title: Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012.
abstract: Treatment of renal-cell carcinoma has progressed over the past decade, in terms of surgical and systemic therapy. Current treatment guidelines are based on clinical evidence, but do not take into account resource limitations among different countries. These limitations, which include financial and logistical challenges and lack of skilled health-care professionals, have the greatest effect in low-income countries. This consolidated statement gives treatment recommendations for renal-cell carcinoma that are based on clinical evidence and stratified according to extent of resource availability. The statement was formulated by a panel of urologists, medical oncologists, and clinical oncologists from Asian countries, at a consensus session on kidney cancer that was held as part of the 2012 Asian Oncology Summit in Singapore. Resource levels are defined according to a four-tier system (basic, limited, enhanced, and maximum), and treatment recommendations are specified based on availability of financial, skill, and logistical resources.
authors.affiliation: Department of Urology, National University Health System, Singapore. surce@nus.edu.sg
authors.forename: Edmund
authors.initials: E
authors.lastname: Chiong
authors.forename: Miah Hiang
authors.initials: MH
authors.lastname: Tay
authors.forename: Min Han
authors.initials: MH
authors.lastname: Tan
authors.forename: Santosh
authors.initials: S
authors.lastname: Kumar
authors.forename: Hong Gee
authors.initials: HG
authors.lastname: Sim
authors.forename: Bin Tean
authors.initials: BT
authors.lastname: Teh
authors.forename: Rainy
authors.initials: R
authors.lastname: Umbas
authors.forename: Noan Minh
authors.initials: NM
authors.lastname: Chau
mesh_terms: D001208:Asia / Q000453:epidemiology; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy; D003906:Developing Countries / Q000191:economics; D019468:Disease Management; D017408:Guidelines as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A